Conference call December 4, 2017 at 5:30
pm ET
LEAMINGTON, ON, Dec. 4, 2017 /CNW/ - Aphria Inc. ("Aphria"
or the "Company") (TSX: APH and US OTC: APHQF) today announced that
it has entered into an agreement to become a medical cannabis
supplier to Shoppers Drug Mart.
Subject to Health Canada's approval of Shoppers Drug Mart's
application to be a licensed producer, under the terms of the
agreement the Company will supply Shoppers Drug Mart with
Aphria-branded medical cannabis products. It is expected the
products will be sold online, as Canadian regulations currently
restrict the sale of medical cannabis in retail pharmacies.
"We have an impeccable record cultivating and producing
high-quality, medical-grade cannabis," said Vic Neufeld, CEO of Aphria. "These traits make
us a strong partner for an organization looking to serve and
support Canadian patients."
CONFERENCE CALL ON DECEMBER 4,
2017
Management will hold a conference call on December 4, 2017 at 5:30
pm ET to discuss the supplier agreement between Aphria and
Shoppers Drug Mart. Interested participants may take part by
dialing (888) 231-8191. A replay of this call will be available
until January 4, 2018 by dialing
(855) 859-2056 with the passcode 6395256.
We Have a Good Thing Growing.
About Aphria
Aphria Inc., one of Canada's
lowest cost producers, produces, supplies and sells medical
cannabis. Located in Leamington,
Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight,
allowing for the most natural growing conditions available. Aphria
is committed to providing pharma-grade medical cannabis, superior
patient care while balancing patient economics and returns to
shareholders.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to internal expectations,
estimated margins, expectations with respect to actual volumes
under the agreement, expectations for future growing capacity and
costs, the completion of any capital project or expansions, and
expectations with respect to future production costs.
Forward-looking statements necessarily involve known and unknown
risks, including, without limitation, risks associated with general
economic conditions; adverse industry events; marketing costs; loss
of markets; future legislative and regulatory developments
involving medical marijuana; inability to access sufficient capital
from internal and external sources, and/or inability to access
sufficient capital on favourable terms; the medical marijuana
industry in Canada generally,
income tax and regulatory matters; the ability of Aphria to
implement its business strategies; competition; crop failure;
currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE Aphria Inc.